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Abstract
Many bacterial and viral pathogens (or their toxins), including Pseudomonas aeruginosa
exotoxin A, require processing by host pro-protein convertases such as furin to cause dis-
ease. We report the development of a novel irreversible inhibitor of furin (QUB-F1) consist-
ing of a diphenyl phosphonate electrophilic warhead coupled with a substrate-like peptide
(RVKR), that also includes a biotin tag, to facilitate activity-based profiling/visualisation.
QUB-F1 displays greater selectivity for furin, in comparison to a widely used exemplar com-
pound (furin I) which has a chloromethylketone warhead coupled to RVKR, when tested
against the serine trypsin-like proteases (trypsin, prostasin and matriptase), factor Xa and
the cysteine protease cathepsin B. We demonstrate QUB-F1 does not prevent P. aerugi-
nosa exotoxin A-induced airway epithelial cell toxicity; in contrast to furin I, despite inhibiting
cell surface furin-like activity to a similar degree. This finding indicates additional proteases,
which are sensitive to the more broad-spectrum furin I compound, may be involved in this
process.
Introduction
Furin is a type I transmembrane serine protease ubiquitously expressed in vertebrates that
cycles from the trans-Golgi network through the endosomal system to the cell membrane and
back [1]. Furin catalyses the hydrolysis of precursor peptide and protein substrates including
receptors, hormones and cell surface proteins [2]. Numerous reports demonstrate that furin
contributes to the pathology of a variety of diseases via the activation of several viral and bacte-
rial pathogenic proteins, including P. aeruginosa exotoxin A (PEA) [3,4]. Chronic infection of
the airways by P. aeruginosa is a central feature of cystic fibrosis (CF) lung disease [5], with
PEA detected in the respiratory secretions of patients with CF [6]. Antibodies to PEA have also
been identified in the sera of CF patients suffering from chronic P. aeruginosa infection [7].
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The mortality rate among patients infected with PEA-producing P. aeruginosa isolates has
been reported as 3 times higher compared with infected non-producers [8]. Furin is also impli-
cated in tumorigenesis, atherosclerosis, diabetes and neurodegenerative disorders such as Alz-
heimer’s disease [3,9,10]. Novel furin inhibitors are therefore of prime importance as research
tools and potential therapeutic agents.
A number of synthetic furin inhibitors have been developed over recent decades including
the widely used compound furin I (Decanoyl-RVKR-chloromethylketone (CMK)). Furin I
contains a specificity element (RVKR) based on furin substrate specificity for the consensus
amino acid sequence Arg-X-Lys/Arg-Arg (where X is any amino acid and indicates the point
of cleavage).
Peptidyl chloromethyl ketones (CMK) were originally identified as potent inhibitors of ser-
ine proteases [11,12] forming irreversible transition state analogues through rapid alkylation of
the active-site histidine residue. These compounds have been employed widely for obtaining
valuable crystallographic information on the structure of protease active-sites and thus
highlighting their proteolytic mechanisms. Unfortunately, a number of drawbacks are associ-
ated with the use of CMK-based inhibitors, which limits their potential value and application.
The highly electrophilic CMK warhead has subsequently been shown to display poor selectivity
for serine proteases resulting in alkylation of both cysteine proteases including cathepsin B
[11,13] and the active-site threonine residue of the proteasome [14]. Furthermore bionucleo-
philes such as glutathione are also rapidly alkylated by the CMK electrophile [15]. In addition,
CMKs also possess poor aqueous stability [15] as a consequence of the highly reactive nature of
the warhead, limiting their utilisation in biological studies.
The application of biotinylated active site-directed inhibitors or affinity labels was pioneered
within our group as a method to allow for the disclosing and profiling of cysteine and serine
proteolytic activities in various biological media. These affinity labels allow for the detection of
proteases containing the active-site tethered biotinylated affinity labels following disclosure
using streptavidin-based systems. This work was initially carried out with biotinylated peptidyl
diazomethane probes for cathepsin B-like proteases [16] and was also shown to be applicable
with the use of peptidyl CMK probes [17]. Similarly, we were also the first group to synthesise
biotinylated peptidyl diphenyl phosphonate compounds that specifically inhibit serine prote-
ases and display less limitations than peptidyl CMKs. These were subsequently applied to the
selective disclosure and detection of serine proteases produced by breast cancer cells [18] and
the digenetic trematode Haplometra cylindracea [19]. Herein we report the development of a
novel compound Nα-Pal-Nω-(Biotinyl-Ahx)-Lys-RVKRP(OPh)2 (QUB-F1) consisting of a
furin specificity element (RVKR) and a diphenyl phosphonate electrophilic warhead. We
hypothesised that QUB-F1 would exhibit a greater degree of selectivity than the highly reactive
furin I. The incorporation of a biotin moiety also facilitates visualisation and activity profiling
of furin-like proteases. As a more selective inhibitor of furin, QUB-F1 was subsequently used
to investigate the role of furin in the activation of PEA.
Materials and Methods
Materials
Recombinant human enzymes were sourced as follows: furin and matriptase (R&D Systems);
prostasin (Sino Biological); trypsin and chymotrypsin (Sigma-Aldrich); factor Xa and neutro-
phil elastase (Merck Millipore) and proteinase-3 and cathepsin G (Elastin Products, Missouri).
Fluorogenic substrates were sourced as follows: p-Glu-Arg-Thr-Lys-Arg-NH2Mec and Boc-
Gln-Ala-Arg-NH2Mec (R&D Systems); Boc-Ile-Glu-Gly-Arg-NH2Mec (Bachem); Z-Gly-Gly-
Arg-NH2Mec, MeOSuc-Ala-Ala-Pro-Val-NH2Mec and Suc-Ala-Ala-Pro-Phe-NH2Mec
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(Sigma-Aldrich). All chemicals and reagents for the synthesis of QUB-F1 were supplied by
Sigma-Aldrich unless otherwise indicated. Fmoc-Lys(Boc)-SASRIN resin was sourced from
Bachem. Fmoc-protected amino acids and HCTU were supplied by Merck Millipore.
QUB-F1 synthesis
QUB-F1 (S1 Fig) was synthesised using a combination of solid and solution phase methodolo-
gies. H-Nω,Nω’-(di-Boc)-ArgP(OPh)2 was synthesised as described previously [20]. The pro-
tected peptide Nα-Pal-Nω-(Biotinyl-Ahx)-Lys-Nω,Nω’-(di-Boc)-Arg-Val-Nω-(Boc)-Lys-OH
was synthesised on a Fmoc-Lys(Boc)-SASRIN resin using standard Fmoc/t-Butyl methodolo-
gies, followed by cleavage with 1% (v/v) trifluoroacetic acid/dichloromethane. The protected
peptide acid was subsequently coupled toH-Nω,Nω’-(di-Boc)-ArgP(OPh)2 in a HCTU-medi-
ated condensation reaction and final deprotection was carried out with trifluoroacetic acid.
Confirmation of the correct compound was achieved through HPLC and mass spectroscopy.
ESI-MSm/z 363.15 [M + 4H+]/4 (calculated C72H123N16O11PS: 1451.91).
Determination of second order rate constant (QUB-F1 versus
recombinant human furin)
A range of final inhibitor concentrations (at least 5) were prepared from a 10 mM stock solu-
tion of QUB-F1 (in N,N-dimethyformamide (DMF)). The fluorogenic substrate, p-Glu-Arg-
Thr-Lys-Arg-NH2Mec (pERTKR-AMC), was diluted in assay buffer (25 mM Tris/HCl con-
taining 1 mM CaCl2, pH 7.4) and used at a fixed concentration of 50 μM throughout. All inhi-
bition assays were performed in microtitre plates maintained at 37°C in a final volume of
100 μl. The reaction was initiated by the addition of recombinant human furin (0.01 μg/well)
and the rate of substrate hydrolysis continuously recorded at λex 360 nm, λem 480 nm, over a
period of 90 minutes using a FLUOstar Optima microplate reader (BMG Labtech). The resul-
tant inhibition progress curve for QUB-F1 was then analysed according to the kinetic models
developed by Tian and Tsou [21] andWalker and Elmore [22], for irreversible inhibitors,
using GRAFIT (Erithacus Software). The inhibitor constant Ki, the apparent first order rate
constant k3, and over all second-order rate constant (k3/Ki) for QUB-F1 against furin was
determined, from a plot of 1/A against [I] (where A is the apparent second-order rate constant
for irreversible inhibition determined for each inhibitor concentration [I]). The determination
of Km and Vmax were also determined separately by fitting initial rates of hydrolysis to substrate
concentration, according to Michaelis-Menten kinetics, also using GRAFIT (Erithacus Soft-
ware). The inhibitor constant Ki, the apparent first order rate constant k3, and the overall sec-
ond-order rate constant (k3/Ki) for QUB-F1 against furin were determined, from a plot of 1/A
against [I] (where A is the apparent second-order rate constant for irreversible inhibition deter-
mined for each inhibitor concentration [I]).
Fluorogenic protease activity assays
Recombinant protease activities were assessed using the cognate fluorogenic substrates (final
concentration 50 μM) as follows: trypsin (Z-Gly-Gly-Arg-NH2Mec), prostasin and matriptase
(Boc-Gln-Ala-Arg-NH2Mec), factor Xa (Boc-Ile-Glu-Gly-Arg-NH2Mec), neutrophil elastase
and proteinase 3 (MeO-Suc-Ala-Ala-Pro-Val-NH2Mec), chymotrypsin and cathepsin G (Suc-
Ala-Ala-Pro-Phe-NH2Mec). The rate of substrate hydrolysis in the presence or absence of
furin inhibitors was assessed by continuous recording at λex 360 nm, λem 480 nm, over a period
of 60 minutes using a FLUOstar Optima microplate reader (BMG Labtech).
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Western blotting analysis
Recombinant human furin (0.4 μg) was incubated with QUB-F1 (100 μM) for 45 minutes at
37°C. The sample was then denatured and reduced in Laemmli treatment buffer for 5 minutes
at 95°C, resolved by SDS-PAGE, before transfer onto a nitrocellulose membrane which was
blocked with a solution of Tris-buffered saline (TBS) containing 3% (w/v) bovine serum albu-
min and 0.1% (v/v) Tween-20. The membrane was subsequently probed with a streptavidin-
Horseradish peroxidase conjugate (1:10,000) (Vector-Laboratories) in blocking solution for 1 h
prior to detection by chemiluminescence (Luminata Forte Western HRP substrate
(Millipore)).
Cell culture
The CuFi-1 cell line was derived from human airway epithelium of a CF patient (F508del/
F508del) transformed with a reverse transcriptase component of telomerase, hTERT and
human papillomavirus type 16 E6 and E7 genes [23]. Cells were grown as submerged cultures
using bronchial epithelial growth medium (BEBM including a supplement pack) containing:
epidermal growth factor, hydrocortisone, bovine pituitary extract, transferrin, bovine insulin,
triiodothyronine, epinephrine, retinoic acid, penicillin-streptomycin (0.025 μg/ml), gentamy-
cin (0.05 ng/ml) and amphotericin (25 μg/ml).
Cytotoxicity assay
Cytotoxicity was determined using the LDH-Cytotoxicity Colorimetric Assay Kit II (Bio
Vision) in accordance with the instructions provided by the manufacturer. Addition of the sup-
plied cell lysis solution to control wells was used to determine 100% cytotoxicity in each set of
experiments.
Epithelial cell surface furin-like activity assay
Cell culture media was removed from CuFi-1 epithelial cells grown in 96 well microtitre plates
(Thermo Scientific Sterilin; clear bottom, black walled) and replaced with PBS /+ inhibitor
compounds (furin I or QUB-F1). The furin fluorogenic substrate (pERTKR -NH2Mec) was
then applied directly to the cell cultures to give a final concentration of 50 μM. Cell surface pro-
teolytic activity was measured by monitoring the formation of–NH2Mec at λex 360 nm and λem
480 nm using a 5 mm orbital scan every 60 s over a 1 h period (FLUOstar Optima microplate
reader; BMG Labtech).
Statistics
Results are expressed as the means ± s.e.m. with statistically significant differences determined
using a two-tailed Student’s t test, with P<0.05 deemed significant.
Results and Discussion
The ability of QUB-F1 to inhibit recombinant human furin was assessed using a steady-state
fluorimetric assay employing the cognate fluorescent substrate (pERTKR-NH2Mec). The k3, Ki
and k3/Ki values where determined as follows: Ki 9.33 (± 0.32) x 10
−7 M, k3 0.016 (± 0.004)
min-1 and k3/Ki 2.05 (± 0.112) x 10
4 M-1 min-1. This is an increase in potency in comparison to
the previously reported single amino-acid broad-spectrum inhibitor QUB-TL1 [20]. The
improved inhibitory potency can be attributed to the inclusion of a furin specificity sequence
(RVKR) within QUB-F1 providing increased affinity for the furin active site. The kinetic data
is also consistent with QUB-F1 acting as an irreversible inhibitor, forming an irreversible
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covalent complex with the furin active-site. This was confirmed by Western blotting where
recombinant human furin inactivated by QUB-F1 and denatured under reducing conditions
allowed successful visualization by streptavidin-HRP (which detects the biotin tag incorporated
into the compound) (Fig 1). This observation highlights QUB-F1 may potentially be employed
as a research tool enabling profiling of furin activity in biological samples.
In order to assess their respective selectivity of action, QUB-F1 and furin I were tested
against a selection of serine proteases (trypsin, prostasin, matriptase, factor Xa neutrophil elas-
tase, proteinase 3, cathepsin G and chymotrypsin) relevant in CF airways. Furin I (10 μM) caused
significant inhibition of trypsin-like enzymes (trypsin, prostasin and matriptase) and factor Xa;
in contrast to QUB-F1 (10 μM) which did not (Fig 2A–2D), indicating improved selectivity of
the latter. Neither compound was found to inhibit neutrophil elastase, proteinase 3, cathepsin G
or chymotrypsin (Fig 2E–2H). Since previous work has demonstrated that peptidyl CMKs inhibit
cysteine proteases irreversibly [11]; we performed a head to head comparison on the ability of
furin I (an example inhibitor of this type) and QUB-F1 to inhibit the lysosomal cysteine protease
cathepsin B. Furin I potently inhibits this enzyme (IC50 0.056 μM), whereas QUB-F1 displayed
no inhibitory action up to and including a concentration of 10 μM) (Fig 3).
Furin has been implicated in the processing of PEA resulting in the generation of a 37 kDa
C-terminal fragment that translocates to the cytosol causing cell death by affecting protein syn-
thesis of host cells [24]. As furin I has previously been shown to protect CF airway epithelial
cells from the toxic actions of PEA [25], we sought to determine whether QUB-F1 would have
a similar impact. As expected, furin I significantly reduced PEA-induced epithelial cell toxicity
in our study (Fig 4A). In contrast, however, QUB-F1 offered no protection against PEA-
induced cell death (Fig 4A) even though this compound inhibited cell surface furin-like activity
to the same extent as furin I (Fig 4B). Together these data suggest the involvement of proteases,
in addition to furin in this process, which are not inhibited by the more specific QUB-F1
compound (Figs 2 and 3). Indeed cysteine cathepsins, which are inhibited by furin I, have pre-
viously been implicated in the PEA intoxication process [26]. The involvement of additional
Fig 1. Irreversible inhibition and visualization of recombinant human furin by QUB-F1.Western blot
analysis was performed under reducing and denaturing conditions demonstrating QUB-F1 (100 μM) is
irreversibly bound to furin (0.4 μg). The inhibitor-proteases complex can be visualized using streptavidin-
HRP, which detects the biotin reporter group on the compound.
doi:10.1371/journal.pone.0159868.g001
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proteases is further indicated in experiments using furin deficient cells wherein some sensitivity
to PEA is retained [27].
Future studies utilising furin-deficient and expressing cell lines, and a range of selective pro-
tease inhibitors (including for trypsin-like and cysteine proteases) may prove useful in further
characterising the underlying molecular mechanisms of the PEA intoxication process; and also
allow further analysis concerning the specificity of furin inhibitors including QUB-F1. More-
over whilst the current study has focused on PEA intoxication one should note several bacterial
toxins including anthrax toxin, aerolysin toxin (a causative agent in many food-borne ill-
nesses), shiga toxin and diphtheria toxin are activated by furin [3]. As such it would be of inter-
est to examine the impact of QUB-F1 in this wider context.
Fig 2. Evaluation of the selectivity of action of QUB-F1 and furin I versus a selection of serine proteases. Trypsin (A), matriptase (B),
prostasin (C), factor Xa (D), neutrophil elastase (E), proteinase 3 (F), cathepsin G (G) and chymotrypsin (H) activity was assessed using their
cognate fluorogenic substrates in the presence or absence of 10 μM inhibitor (QUB-F1 or furin I) (N = 3). Data represent mean ± s.e.m.;
***P<0.001.
doi:10.1371/journal.pone.0159868.g002
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In summary we have developed a novel diphenyl phosphonate-based irreversible inhibitor
of furin (QUB-F1) that displays enhanced selectively when compared to the widely employed
compound furin I. We believe this improved selectivity may enable improved interpretation of
the role of furin in biological processes. This is exemplified by our studies evaluating the impact
of QUB-F1 and furin I on PEA-induced cytotoxicity. Here we show that only the latter (less
specific) compound rescues the cells indicating the potential involvement of other serine and
Fig 3. Comparison of QUB-F1 and furin I versus cathepsin B. Cathepsin B activity was assessed in the presence or
absence of various concentrations of QUB-F1 or furin I (N = 3). Data represent mean ± s.e.m.
doi:10.1371/journal.pone.0159868.g003
Fig 4. Effect of furin inhibitors on PEA-induced epithelial cell toxicity. (A) Cell toxicity (%) induced by 2 μg/ml PEA (24 h) was
measured in the presence or absence of furin I or QUB-F1. Data represent mean ± s.e.m. *P<0.05. (B) Airway epithelial cell surface furin-
like activity was assayed upon application of the furin fluorogenic substrate (pERTKR) to cell cultures in the presence or absence of
10 μM furin I or QUB-F1.
doi:10.1371/journal.pone.0159868.g004
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cysteine proteases, in addition to furin in this process. We caution against conclusions obtained
when non-selective inhibitors such as furin I are used within biological model systems.
Supporting Information
S1 Fig. Structure of QUB-F1 and furin I.
(TIF)
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